---
schema_version: "secwatch.filing_event.v1"
accession: "0001815776-26-000051"
form_type: "8-K"
ticker: "LENZ"
cik: "0001815776"
company_name: "LENZ Therapeutics, Inc."
filed_at: "2026-08-11T20:08:36+00:00"
generated_at: "2026-08-11T20:10:32.068282+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# LENZ Q2 2026 revenue $5.5M, net loss $31.9M; VIZZ launch shows strong refill trends

## Summary
- Q2 total revenue $5.5M: product sales $1.7M (~27k packs) + license revenue $3.8M (incl. $2.5M Théa milestone, $1.25M Everest sublicense).
- Net loss $31.9M for Q2 ($1.02/share) vs $14.9M loss ($0.53/share) in Q2 2025; SG&A up to $39.4M on launch investment.
- Over 60% of ePharmacy patients bought multiple packs; Q4'25/Q1'26 cohorts tracking to 5 packs/year; >13,000 unique prescribers, ~75% repeat.
- Cash $220.0M as of June 30, 2026; launched telehealth in July 2026 and nationwide TV ads with Sarah Jessica Parker.
- Regulatory progress: MAA to UK MHRA, Health Canada NDS filed, Arrotex deal for Australia/NZ, Everest sublicense for Greater China.

## SEC filing metadata
- accession: 0001815776-26-000051
- form_type: 8-K
- ticker: LENZ
- cik: 0001815776
- company_name: LENZ Therapeutics, Inc.
- filed_at: 2026-08-11T20:08:36+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1815776/000181577626000051/0001815776-26-000051-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1815776/000181577626000051/lenz-20260811.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001815776-26-000051
- JSON: https://secwatch.observer/filing/0001815776-26-000051.json
- Plain text: https://secwatch.observer/filing/0001815776-26-000051.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.